Xingyao Kunze Biomedical
RNAi and antibody therapies for chronic liver diseases.
About Xingyao Kunze Biomedical
Hepa Thera, legally known as Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd., is a clinical-stage biotechnology company developing therapies for liver diseases, with a primary focus on achieving a functional cure for chronic hepatitis B (CHB). The company was established in May 2021 and is headquartered in Shanghai, China. It was incubated by Fosun Health Capital, following an innovation model inspired by Flagship Pioneering. On May 6, 2026, the company appointed Dr. Wu Kai as its Chief Executive Officer. In a significant financial development, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced on May 26, 2026, its intention to invest CNY 414 million to acquire a 20.87% stake in the company. Hepa Thera's core strategy centers on a dual-technology platform combining RNA interference (RNAi) and monoclonal antibodies to create effective combination therapies. The company's lead product pipeline targets chronic hepatitis B, a major global health issue affecting over 300 million people worldwide. Its main drug candidates are HT-101 and HT-102. HT-101 is a GalNAc-conjugated small interfering RNA (siRNA) designed to specifically silence hepatitis B viral transcripts, essentially stopping the production of viral proteins at the source. HT-102 is a neutralizing monoclonal antibody that clears circulating viral proteins, which helps restore the body's own immune control over the virus. This combination therapy has shown promising results in clinical trials, with a Phase 2 study demonstrating a 79% clearance rate of the hepatitis B surface antigen (HBsAg) at 24 weeks. The company is in the clinical trial stage of development and does not yet have commercial revenue. Its drug candidate HT-101 received Breakthrough Therapy Designation from China's Center for Drug Evaluation (CDE) as a monotherapy. The combination of HT-101 and HT-102 also received this designation from the NMPA. Furthermore, the U.S. FDA has cleared the initiation of Phase II clinical trials for the combination therapy. Beyond hepatitis B, Hepa Thera's pipeline extends to other unmet needs in liver disease, including hepatitis D, MASH (Metabolic dysfunction-associated steatohepatitis), and liver fibrosis, utilizing technologies such as fusion proteins and mRNA-based immunotherapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Genetics and genomics, RNA
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2026 | $54M | $294M | Tahoe Venture · Humble Capital · TG Sino-Dragon Fund · Jiaxing Deshi Private Equity Fund Management | ↗ |
Growth signals
Latest recorded traffic for Xingyao Kunze Biomedical is 450 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Tychobio.aiAI platform for designing RNA-based therapies. |
Saint-Mandé, France | Operational | 5 | — | — |
JAMA TxExosome-based therapeutics for cardiogenetic diseases |
Utrecht, Netherlands | Operational | |||
| New York City, United States | Operational | ||||
ReThink64 BionetworksIntercellular router system for large-molecule drug delivery |
Fremont, United States | Operational | |||
Therna BiosciencesAI-powered platform designing programmable RNA medicines |
San Carlos, United States | Operational | |||
Vivatides TherapeuticsNext-generation, extra-hepatic targeted RNA therapeutics |
Woburn, United States | Operational | |||
falcon-hd.comOral RNA splicing modifiers targeting genetic diseases like Huntington's by modulating protein expression and slowing disease progression |
— | Operational | |||
| China | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xingyao Kunze Biomedical in the Suzhou Shi ecosystem
The Xingyao Kunze Biomedical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- TVTahoe Venture
- HCHumble Capital
- TFTG Sino-Dragon Fund
- JMJiaxing Deshi Private Equity Fund Management
Shanghai Fosun Pharmaceutical- KCKaitai Capital
Huajin Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xingyao Kunze Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xingyao Kunze Biomedical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







